A randomized, active-controlled phase 3 study of ivonescimab FOLFOX versus bevacizumab FOLFOX as first-line treatment of metastatic colorectal cancer: HARMONi-GI3

Summit Therapeutics Inc. published this content on May 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 30, 2026 at 17:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]